Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression

Journal of Immunology

Volumn 184, Issue 5, 2010, Pages 2321-2328

  Ren, Guangwen ^a   Zhao, Xin ^a   Zhang, Liying ^a   Zhang, Jimin ^a   L'Huillier, Andrew ^a   Ling, Weifang ^a   Roberts, Arthur I ^a   Le, Anh D ^c   Shi, Songtao ^c   Shao, Changshun ^b   Shi, Yufang ^a,d  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL INTERACTION; COCULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE DELETION; GENE FUNCTION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, NEUTRALIZING; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; FEMALE; FLOW CYTOMETRY; IMMUNOSUPPRESSION; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; INTERLEUKIN-1; MALE; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, INTERFERON; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 77951889580     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902023     Document Type: Article

References (51)

1. Pittenger, M. F., A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. Mosca, M. A. Moorman, D. W. Simonetti, S. Craig, and D. R. Marshak. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147. (Pubitemid 29282067)
2. Le Blanc, K., I. Rasmusson, B. Sundberg, C. Götherström, M. Hassan, M. Uzunel, and O. Ringdén. 2004. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363: 1439-1441. (Pubitemid 38586721)
3. Krampera, M., S. Glennie, J. Dyson, D. Scott, R. Laylor, E. Simpson, and F. Dazzi. 2003. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101: 3722-3729. (Pubitemid 36857965)
4. Corcione, A., F. Benvenuto, E. Ferretti, D. Giunti, V. Cappiello, F. Cazzanti, M. Risso, F. Gualandi, G. L. Mancardi, V. Pistoia, and A. Uccelli. 2006. Human mesenchymal stem cells modulate B-cell functions. Blood 107: 367-372. (Pubitemid 43053565)
5. Jiang, X. X., Y. Zhang, B. Liu, S. X. Zhang, Y. Wu, X. D. Yu, and N. Mao. 2005. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105: 4120-4126. (Pubitemid 40656164)
6. Spaggiari, G. M., A. Capobianco, S. Becchetti, M. C. Mingari, and L. Moretta. 2006. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107: 1484-1490.
7. Batten, P., P. Sarathchandra, J. W. Antoniw, S. S. Tay, M. W. Lowdell, P. M. Taylor, and M. H. Yacoub. 2006. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng. 12: 2263-2273. (Pubitemid 44734984)
8. Groh, M. E., B. Maitra, E. Szekely, and O. N. Koç. 2005. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol. 33: 928-934.
9. Ryan, J. M., F. P. Barry, J. M. Murphy, and B. P. Mahon. 2005. Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. (Lond.) 2: 8.
10. Aggarwal, S., and M. F. Pittenger. 2005. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815-1822. (Pubitemid 40223708)
11. Ren, G., L. Zhang, X. Zhao, G. Xu, Y. Zhang, A. I. Roberts, R. C. Zhao, and Y. Shi. 2008. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2: 141-150. (Pubitemid 351181031)
12. Sato, K., K. Ozaki, I. Oh, A. Meguro, K. Hatanaka, T. Nagai, K. Muroi, and K. Ozawa. 2007. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109: 228-234. (Pubitemid 46053063)
13. Krampera, M., L. Cosmi, R. Angeli, A. Pasini, F. Liotta, A. Andreini, V. Santarlasci, B. Mazzinghi, G. Pizzolo, F. Vinante, et al. 2006. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24: 386-398.
14. Quaedackers, M. E., C. C. Baan, W. Weimar, and M. J. Hoogduijn. 2009. Cell contact interaction between adipose-derived stromal cells and allo-activated T lymphocytes. Eur. J. Immunol. 39: 3436-3446.
15. Liu, X., A. Samouilov, J. R. Lancaster, Jr., and J. L. Zweier. 2002. Nitric oxide uptake by erythrocytes is primarily limited by extracellular diffusion not membrane resistance. J. Biol. Chem. 277: 26194-26199.
16. Lancaster, J. R., Jr. 1997. A tutorial on the diffusibility and reactivity of free nitric oxide. Nitric Oxide 1: 18-30.
17. Porterfield, D. M., J. D. Laskin, S. K. Jung, R. P. Malchow, B. Billack, P. J. Smith, and D. E. Heck. 2001. Proteins and lipids define the diffusional field of nitric oxide. Am. J. Physiol. Lung Cell. Mol. Physiol. 281: L904-L912.
18. Pribila, J. T., A. C. Quale, K. L. Mueller, and Y. Shimizu. 2004. Integrins and T cell-mediated immunity. Annu. Rev. Immunol. 22: 157-180.
19. Isobe, M., J. Suzuki, S. Yamazaki, Y. Yazaki, S. Horie, Y. Okubo, K. Maemura, Y. Yazaki, and M. Sekiguchi. 1997. Regulation by differential development of Th1 and Th2 cells in peripheral tolerance to cardiac allograft induced by blocking ICAM-1/LFA-1 adhesion. Circulation 96: 2247-2253.
20. Shimada, Y., M. Hasegawa, Y. Kaburagi, Y. Hamaguchi, K. Komura, E. Saito, K. Takehara, D. A. Steeber, T. F. Tedder, and S. Sato. 2003. L-selectin or ICAM-1 deficiency reduces an immediate-type hypersensitivity response by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity. J. Immunol. 170: 4325-4334. (Pubitemid 36428202)
21. Xu, G., L. Zhang, G. Ren, Z. Yuan, Y. Zhang, R. C. Zhao, and Y. Shi. 2007. Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. Cell Res. 17: 240-248. (Pubitemid 46438724)
22. Ren, G., J. Su, X. Zhao, L. Zhang, J. Zhang, A. I. Roberts, H. Zhang, G. Das, and Y. Shi. 2008. Apoptotic cells induce immunosuppression through dendritic cells: critical roles of IFN-gamma and nitric oxide. J. Immunol. 181: 3277-3284.
23. Bromley, S. K., W. R. Burack, K. G. Johnson, K. Somersalo, T. N. Sims, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. Dustin. 2001. The immunological synapse. Annu. Rev. Immunol. 19: 375-396.
24. Chamberlain, G., J. Fox, B. Ashton, and J. Middleton. 2007. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25: 2739-2749. (Pubitemid 350127858)
25. Segers, V. F., I. Van Riet, L. J. Andries, K. Lemmens, M. J. Demolder, A. J. De Becker, M. M. Kockx, and G. W. De Keulenaer. 2006. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. Am. J. Physiol. Heart Circ. Physiol. 290: H1370-H1377.
26. Choi, J., D. R. Enis, K. P. Koh, S. L. Shiao, and J. S. Pober. 2004. T lymphocyte-endothelial cell interactions. Annu. Rev. Immunol. 22: 683-709.
27. Bevilacqua, M. P. 1993. Endothelial-leukocyte adhesion molecules. Annu. Rev. Immunol. 11: 767-804.
28. Ren, G., J. Su, L. Zhang, X. Zhao, W. Ling, A. L'huillie, J. Zhang, Y. Lu, A. I. Roberts, W. Ji, et al. 2009. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27: 1954-1962.
29. Hofmann, N., N. Lachnit, M. Streppel, B. Witter, W. F. Neiss, O. Guntinas-Lichius, and D. N. Angelov. 2002. Increased expression of ICAM-1, VCAM-1, MCP-1, and MIP-1 alpha by spinal perivascular macrophages during experimental allergic encephalomyelitis in rats. BMC Immunol. 3: 11. (Pubitemid 38692915)
30. Kawai, K., Y. Kobayashi, M. Shiratori, G. Sobue, T. Tamatani, M. Miyasaka, and Y. Yoshikai. 1996. Intrathecal administration of antibodies against LFA-1 and against ICAM-1 suppresses experimental allergic encephalomyelitis in rats. Cell. Immunol. 171: 262-268.
31. Littler, A. J., C. D. Buckley, P. Wordsworth, I. Collins, J. Martinson, and D. L. Simmons. 1997. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br. J. Rheumatol. 36: 164-169.
32. Schulze-Koops, H., P. E. Lipsky, A. F. Kavanaugh, and L. S. Davis. 1995. Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J. Immunol. 155: 5029-5037.
33. Aronni, S., M. Cortes, M. Sacchetti, A. Lambiase, A. Micera, R. Sgrulletta, and S. Bonini. 2006. Upregulation of ICAM-1 expression in the conjunctiva of patients with chronic graft-versus-host disease. Eur. J. Ophthalmol. 16: 17-23.
34. Bullard, D. C., L. A. Hurley, I. Lorenzo, L. M. Sly, A. L. Beaudet, and N. D. Staite. 1996. Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. J. Immunol. 157: 3153-3158. (Pubitemid 126450077)
35. Sostak, P., P. Reich, C. S. Padovan, A. Gerbitz, E. Holler, and A. Straube. 2004. Cerebral endothelial expression of adhesion molecules in mice with chronic graft-versus-host disease. Stroke 35: 1158-1163. (Pubitemid 38543536)
36. Rose, J. W., C. T. Welsh, K. E. Hill, M. K. Houtchens, R. S. Fujinami, and J. J. Townsend. 1999. Contrasting effects of anti-adhesion molecule therapy in experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis. J. Neuroimmunol. 97: 110-118.
37. Carter, R. A., I. K. Campbell, K. L. O'Donnel, and I. P. Wicks. 2002. Vascular cell adhesion molecule-1 (VCAM-1) blockade in collagen-induced arthritis reduces joint involvement and alters B cell trafficking. Clin. Exp. Immunol. 128: 44-51.
38. Gauvreau, G. M., A. B. Becker, L. P. Boulet, J. Chakir, R. B. Fick, W. L. Greene, K. J. Killian, P. M. O'byrne, J. K. Reid, and D. W. Cockcroft. 2003. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J. Allergy Clin. Immunol. 112: 331-338.
39. Mileski, W. J., D. Burkhart, J. L. Hunt, R. J. Kagan, J. R. Saffle, D. N. Herndon, D. M. Heimbach, A. Luterman, R. W. Yurt, C. W. Goodwin, and J. Hansborough. 2003. Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury. J. Trauma 54: 950-958.
40. Yacyshyn, B. R., W. Y. Chey, J. Goff, B. Salzberg, R. Baerg, A. L. Buchman, J. Tami, R. Yu, E. Gibiansky, and W. R. Shanahan; ISIS 2302-CS9 Investigators. 2002. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51: 30-36.
41. Yonekawa, K., and J. M. Harlan. 2005. Targeting leukocyte integrins in human diseases. J. Leukoc. Biol. 77: 129-140.
42. Targan, S. R., B. G. Feagan, R. N. Fedorak, B. A. Lashner, R. Panaccione, D. H. Present, M. E. Spehlmann, P. J. Rutgeerts, Z. Tulassay, M. Volfova, et al; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. 2007. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132: 1672-1683.
43. Lew, E. A., and E. M. Stoffel. 2003. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348: 24-32.
44. Polman, C. H., P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, J. T. Phillips, F. D. Lublin, G. Giovannoni, A. Wajgt, et al; AFFIRM Investigators. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354: 899-910.
45. Miller, D. H., O. A. Khan, W. A. Sheremata, L. D. Blumhardt, G. P. Rice, M. A. Libonati, A. J. Willmer-Hulme, C. M. Dalton, K. A. Miszkiel, and P. W. O'Connor; International Natalizumab Multiple Sclerosis Trial Group. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348: 15-23.
46. Salmela, K., L. Wramner, H. Ekberg, I. Hauser, O. Bentdal, L. E. Lins, H. Isoniemi, L. Bäckman, N. Persson, H. H. Neumayer, et al. 1999. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation 67: 729-736.
47. Ulbrich, H., E. E. Eriksson, and L. Lindbom. 2003. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol. Sci. 24: 640-647.
48. Wang, X., H. Hisha, S. Taketani, Y. Adachi, Q. Li, W. Cui, Y. Cui, J. Wang, C. Song, T. Mizokami, et al. 2006. Characterization of mesenchymal stem cells isolated from mouse fetal bone marrow. Stem Cells 24: 482-493. (Pubitemid 44464751)
49. Majumdar, M. K., M. Keane-Moore, D. Buyaner, W. B. Hardy, M. A. Moorman, K. R. McIntosh, and J. D. Mosca. 2003. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J. Biomed. Sci. 10: 228-241.
50. Jones, S., N. Horwood, A. Cope, and F. Dazzi. 2007. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J. Immunol. 179: 2824-2831.
51. Haniffa, M. A., X. N. Wang, U. Holtick, M. Rae, J. D. Isaacs, A. M. Dickinson, C. M. Hilkens, and M. P. Collin. 2007. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J. Immunol. 179: 1595-1604.